Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$78.05
-1.9%
$76.12
$61.24
$82.41
$246.74B0.373.15 million shs4.45 million shs
Cellectis S.A. stock logo
CLLS
Cellectis
$2.99
+3.5%
$2.52
$1.10
$3.35
$160.64M3.0374,655 shs95,666 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%-2.62%+0.49%+8.17%+1.65%
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%+7.84%+1.40%+108.66%+28.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$78.05
-1.9%
$76.12
$61.24
$82.41
$246.74B0.373.15 million shs4.45 million shs
Cellectis S.A. stock logo
CLLS
Cellectis
$2.99
+3.5%
$2.52
$1.10
$3.35
$160.64M3.0374,655 shs95,666 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.00%-2.62%+0.49%+8.17%+1.65%
Cellectis S.A. stock logo
CLLS
Cellectis
0.00%+7.84%+1.40%+108.66%+28.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.75
Moderate Buy$86.0010.19% Upside
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.0033.78% Upside

Current Analyst Ratings Breakdown

Latest CLLS and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$97.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.48$6.17 per share12.64$13.18 per share5.92
Cellectis S.A. stock logo
CLLS
Cellectis
$56.30M2.95N/AN/A$2.36 per share1.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.6629.3415.611.4614.68%32.84%12.87%11/11/2025 (Estimated)
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)

Latest CLLS and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million
7/29/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.09$1.09N/A$0.79$14.08 billion$14.46 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.011.29%N/A37.97%N/A
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A

Latest CLLS and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$0.50502%8/8/20258/8/20259/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.55
0.86
0.67
Cellectis S.A. stock logo
CLLS
Cellectis
0.58
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable

Recent News About These Companies

Cellectis S.A. Earnings Call: Progress Amid Challenges
Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$78.05 -1.51 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$77.81 -0.24 (-0.31%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Cellectis stock logo

Cellectis NASDAQ:CLLS

$2.99 +0.10 (+3.46%)
Closing price 04:00 PM Eastern
Extended Trading
$3.00 +0.00 (+0.17%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.